InSightec to Exhibit Non-Invasive Treatment for Uterine Fibroids at 5th Annual World Health Care Congress

TIRAT CARMEL, Israel — InSightec Ltd. today announced that it will exhibit at the 5th Annual World Health Care Congress in Washington, DC from April 21-23. The company will feature the only FDA approved MR Guided Focused Ultrasound Surgery (MRgFUS) device, the ExAblate(R) 2000, which has been used to treat uterine fibroids non-invasively, minimizing trauma, morbidity and recovery time. In addition to enhancing patient care, the procedure has a significant economic impact reducing overall medical costs when compared to conventional surgery. Uterine fibroid is a pervasive condition that impacts up to 70% of women of childbearing age and can lead to serious symptoms.

The company's ExAblate(R) 2000 is the world's first non-invasive surgery system to combine focused ultrasound and magnetic resonance imaging. It received its European CE Marking in 2002 and U.S. Food and Drug Administration approval in 2004 for treating uterine fibroids.

source: Centre Daily Times